Is CT with contrast better than plain CT for assessing retroperitoneal mass?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: February 27, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

From the Guidelines

CT with contrast is the preferred imaging modality over plain CT for assessing retroperitoneal masses. This is because intravenous contrast enhances visualization of these masses by highlighting differences in vascularity between normal tissues and pathological lesions, allowing for better delineation of the mass borders, internal characteristics, and relationship to surrounding structures like blood vessels and organs. The contrast helps distinguish solid from cystic components and can reveal patterns of enhancement that aid in differentiating between various types of masses such as lymphoma, sarcoma, or metastatic disease. According to the UK guidelines for the management of soft tissue sarcomas 1, CT is preferred for diagnosis and managing treatment of retroperitoneal tumors, providing complete staging information on the same scan.

Some key points to consider when using CT with contrast for assessing retroperitoneal masses include:

  • Screening patients for contraindications to contrast, including renal impairment and allergies
  • Adequate hydration before and after the procedure to reduce the risk of contrast-induced nephropathy
  • Using a multiphasic CT protocol, which includes pre-contrast, arterial, venous, and sometimes delayed phases, for optimal imaging
  • Considering MRI as an alternative imaging modality in cases where contrast is absolutely contraindicated

While the ACR Appropriateness Criteria for suspected retroperitoneal bleed 1 discusses the use of IV contrast and CT for initial imaging, the most recent and relevant guideline for assessing retroperitoneal masses is the UK guidelines for the management of soft tissue sarcomas 1, which supports the use of CT with contrast as the preferred imaging modality.

From the Research

CT with Contrast vs Plain CT for Assessing Retroperitoneal Mass

  • The use of CT with contrast is beneficial in assessing retroperitoneal masses, as it provides better definition of tissue planes and contiguous anatomical structures 2.
  • CT is superior to ultrasound in demonstrating the extent of disease, although ultrasound can more easily distinguish cystic from solid masses 2.
  • Non-contrast CT scans may be challenging in evaluating vascular structures, but can still provide useful information in certain cases, such as suspected renal calculus or retroperitoneal hematoma 3.
  • The use of contrast-enhanced CT is recommended for evaluating retroperitoneal tumors, as it provides clinically useful information regarding the presence, size, extent, and composition of the tumors 4.
  • Dynamic contrast-enhanced CT and MRI can be useful in the diagnosis and identification of retroperitoneal localized Castleman's disease, with features such as moderate enhancement in the arterial phase and continuous enhancement in the venous phase 5.
  • Contrast-enhanced CT can also be used to assess the activity of idiopathic retroperitoneal fibrosis, with a significant correlation between SUVmax and CE score, as well as with inflammatory markers such as ESR and CRP 6.

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Research

Diagnosis and evaluation of retroperitoneal tumors by computed tomography.

AJR. American journal of roentgenology, 1977

Research

The value of (18)F-FDG PET/CT in the assessment of active idiopathic retroperitoneal fibrosis.

European journal of nuclear medicine and molecular imaging, 2012

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.